News

According to Medtronic, Attain Ability has the thinnest lead body of any left-heart lead currently available, providing physicians with a tool to deliver therapy directly to hard-to-reach areas

BioElectronics intends to file 510(k) premarket notification for the indication of reducing menstrual pain symptoms with the FDA by the end of May 2009. In the initial pilot

The approval was supported by two placebo-controlled Phase III clinical studies comparing Fanapt to placebo and active control in patients with schizophrenia, as well as safety data from

The Matrix IIb clinical trial which has now completed recruitment is a prospective, randomized, double-blind, placebo-controlled study that screened approximately 285 patients at 30 US medical centers and

The company also received tentative approval on the 500mg tablets and expects to receive final approval on August 3, 2009, upon expiration of the 180-day exclusivity period. Abbott

This large Phase I trial was a randomized, double-blind, placebo-controlled single dose study and comprised 64 healthy adult males, 48 of whom received ErepoXen while 16 received a

Under the terms of the collaboration, which uses Vernalis’s proprietary fragment and structure-based drug discovery platform on this undisclosed cancer target, Vernalis will receive fees and a share

Under the terms of the divestment, Evotec has acquired the assets and operations associated with the zebrafish business currently located in Oxfordshire, UK and Singapore for GBP500,000 in

This designation covers Trinam as a treatment for the prevention of de novo stenosis at vascular surgical anastamoses. Trinam is an adenovirus-mediated VEGF D gene delivered with a